Bacteriophages and phage-delivered CRISPR-Cas system as antibacterial therapy

Ting Kuang Yeh, Shio Shin Jean, Yu Lin Lee, Min Chi Lu, Wen Chien Ko, Hsueh Ju Lin, Po Yu Liu, Po Ren Hsueh

研究成果: Review article同行評審

摘要

Multidrug-resistant (MDR) bacterial infections in humans are increasing worldwide. The global spread of antimicrobial resistance poses a considerable threat to human health. Phage therapy is a promising approach to combat MDR bacteria. An increasing number of reports have been published on phage therapy and the successful application of antibacterials derived using this method. Additionally, the CRISPR-Cas system has been used to develop antimicrobials with bactericidal effects in vivo. The CRISPR-Cas system can be delivered into target bacteria in various ways, with phage-based vectors being reported as an effective method. In this review, we briefly summarise the results of randomised control trials on bacteriophage therapy. Moreover, we integrated mechanisms of the CRISPR-Cas system antimicrobials in a schematic diagram and consolidated the research on phage-delivered CRISPR-Cas system antimicrobials.

原文English
文章編號106475
期刊International journal of antimicrobial agents
DOIs
出版狀態Accepted/In press - 2021

All Science Journal Classification (ASJC) codes

  • 微生物學(醫學)
  • 傳染性疾病
  • 藥學(醫學)

指紋

深入研究「Bacteriophages and phage-delivered CRISPR-Cas system as antibacterial therapy」主題。共同形成了獨特的指紋。

引用此